Anindya Bagchi, PhD

Associate Professor, Department of Urology

Anindya Bagchi

Contact Info

bagch005@umn.edu

Office Phone 612-625-7598

Office Address:
Masonic Cancer Center
3-131 CCRB
2231 6th St SE
Minneapolis, MN 55455

Mailing Address:
Masonic Cancer Research Ctr
1st Floor Mailroom CCRB
2812A (Campus Delivery Code)
2231 6th St SE
Minneapolis, MN 55455

Associate Professor, Department of Urology

Director, Mouse Genetics Laboratory


PhD, Genetics, Jawaharlal Nehru University, India

MS, Biochemistry, University of Calcutta, India

BS, Chemistry, University of Calcutta, India

Postdoctoral Associate, Cancer Genetics, Cold Spring Harbor Laboratory, New York

Summary

Dr. Bagchi received a PhD in Genetics from Jawaharlal Nehru University in India. He conducted postdoctoral research at Cold Spring Harbor Laboratory where he discovered a novel tumor suppressor gene, Chromodomain helicase DNA binding protein 5 (CHD5), which maps in human chromosome 1p36. He joined the faculty at the University of Minnesota in 2008. He is currently the Director of the Univerity's Mouse Genetics Laboratory and a member of the Masonic Cancer Center's Genetic Mechanisms of Cancer Program.

Expertise

Dr. Bagchi studies complex genetic traits in cancer, including the 1p36 locus in which he identified a novel tumor suppressor, the chromodomain helicase DNA-binding protein 5 (CHD5).

Awards & Recognition

2010 Masonic Scholar, Masonic Cancer Center, University of Minnesota

2014 American Cancer Society Research Scholar

2016 Dean's Undergraduate Research Mentor Golden Pipette Award, College of Biological Sciences, University of Minnesota

Professional Associations

New York Academy of Sciences

American Association of Cancer Research

Research

Research Summary/Interests

I have been working on a key genetic variation found in many human cancers, the copy gain of Human 8q24. We have recently uncovered the role of a long noncoding RNA (lncRNA) PVT1 that is co-gained with MYC in most of the 8q24 gain cancer (Tseng et al, PVT1-dependence in cancer with MYC copy-number- increase. Nature, 2014, 512:82-86, Sarver et al, MYC and PVT1 synergize to regulate RSPO1 levels in breast cancer. Cell Cycle, 2016, 15:881-885).

RESEARCH PROJECTS

Role of copy number gain and polymorphism in cancer

Chromosome engineering and chromatin biology in cancer

Research Funding Grants

ACTIVE GRANT SUPPORT
Principal Investigator
125627-RSG- 14-074- 01-TBG - 07/01/2014 – 06/30/2018
American Cancer Society 
Functional Analysis of Low Copy Number Gain of Human 8q24 in Breast Cancer

We propose to investigate the effect of low copy number gain of this region in vivo, and dissect its molecular mechanism, including whether multiple genes in the c-myc- gsdmc region co-operate to affect the transformation and progression of breast cancer and contribute to poor outcome in the patients.

1R01CA200643-01A1 - 07/01/2016-06/30/2021
NIH/NCI
Role of the long non-coding RNA PVT1 in cancer

In this project, we investigate the mechanism by which PVT1 contributes to MYC stability in these cancers, expand our understanding of the role of PVT1 in other cancers where 8q24 is not gained, and finally determine the therapeutic potential of inhibiting PVT1 as a strategy to target MYC-driven cancers. Successful completion of this project will help us to develop new ways to find cure for cancer patients.

Co-Investigator

1R21OD019928-01A1 (PI: Kim) - 05/01/2016 – 01/31/2018
NIH Office of the Director
Development of mouse models for autoinflammatory rare diseases

The objective of this grant is to establish mouse models to recapitulate the multiple autoinflammatory rare syndromes caused by LMP7 point mutations.

5U01HL117664 (PI: Gupta, K)  - 08/15/2013 – 05/31/2018
NIH/NHLBI
Cannabinoid-based therapy and approaches to quantify pain in sickle cell disease

We propose to use transgenic sickle mice, and individual cells involved in evoking pain, to perform this translational study. A proof of principal study in humans will be undertaken to examine the effect of Cannabis ion pain in sickle patients. We expect that the multidisciplinary approach combining biochemistry, neurophysiology, pharmacology, behavior and biomedical engineering will advance the treatment of pain in SCD.

Shared Resource Director
P30CA077598 (PI: Yee) 04/08/2009-01/31/2019
Cancer Center Support Grant

To provide an infrastructure for cancer research, education and patient care for the citizens of the Minnesota and the surrounding region. Our mission is to create a collaborative environment that advances knowledge about the causes, prevention, detection and treatment of cancer.